Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 16/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21326657 | 0.85 | IRAK4 (0.50) | IRAK4MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL21326647 | 0.84 | IRAK4 (0.38) | IRAK4MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL21326725 | 0.84 | IRAK4 (0.56) | IRAK4 | |
| SCHEMBL29773924 | 0.82 | IRAK4 (0.50) | IRAK4MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL21326605 | 0.82 | IRAK4 (0.50) | IRAK4MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL21326682 | 0.80 | CYP1A2 (0.48) | IRAK4MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL29773991 | 0.80 | IRAK4 (0.37) | IRAK4MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL21326713 | 0.79 | DPP4 (0.39) | CYP3A4MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL21326690 | 0.79 | IRAK4 (0.50) | IRAK4ALDH1A1 | |
| SCHEMBL21326679 | 0.79 | MAPT (0.50) | MAPTALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434250-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| CN-109890829-B | Pyrazolo [1,5a ] pyrimidine derivatives as IRAK4 modulators | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20200262845-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| EP-3535273-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2019-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262845-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885CYP3A4 1035/4885MAPT 2095/4885 |
| US-11434250-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885CYP3A4 1035/4885MAPT 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.